knowledge -WSS

knowledge

author：explore 2025-09-29 22:52:31 - browse：85

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

hotspot

WSS

FDA's Pazdur wants cancer trials to range beyond China alone

Why age limits for politicians are a terrible idea

Senate panel eyes new effort on drug shortages

AI can decode, harness the power of the humane immune system

FDA rejects Alnylam's heart disease treatment over insufficient data

Chan Zuckerberg Biohub Chicago to focus on inflammation

explore

knowledge

hotspot

Hollywood unions extend contract negotiations for actors

Cord blood banking comes at a high cost to babies

Guidelines to prevent youth baseball injuries need more muscle

Chan Zuckerberg Biohub Chicago to focus on inflammation

Sports medicine is finally prioritizing gender equality

FDA rejects Alnylam's heart disease treatment over insufficient data

New air purifier tech could be key to improving indoor air quality

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Malaria cases in Florida and Texas: Here’s what you need to know

Chan Zuckerberg Biohub Chicago to focus on inflammation

hotspot

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Letters to First Opinion on caregivers, digital health, and more

VC firm General Catalyst wants to buy a health system

How to increase colonoscopy rates? Looks like an AI can help

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

focus

entertainment

hotspot

explore